Tiffany L Gorman, MD
Family Practice · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gorman’s office at (408) 376-3350 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Checkups this office reported
19 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 87.3 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Appropriate Testing for PharyngitisAs Medicare defines this measure | 3% | 89 |
| Appropriate Treatment for Upper Respiratory Infection (URI)As Medicare defines this measure | 56% | 122 |
| Asked about smokingPatients asked about tobacco, with help to quit if they smoke | 89%That's most of the people this applied to. | 3,666 |
| Blood pressure under controlPeople with high blood pressure whose reading was in a healthy range | 52%That's more than half. | 823 |
| Bone-density scans that were not neededYounger women who got a bone scan without a medical reason | 7%That's few of the people this applied to. Better on this measure. | 657 |
| Breast cancer screeningEligible women who got a mammogram | 76%That's most of the people this applied to. | 1,254 |
| Cervical cancer screeningEligible women who got a Pap or HPV test | 40%That's less than half. | 2,301 |
| Checked for fall riskOlder patients screened for fall risk | 86%That's most of the people this applied to. | 493 |
See the other 11 measures
| Chlamydia Screening for WomenAs Medicare defines this measure | 20% | 243 |
| Colon cancer screeningEligible adults who got a colon cancer test | 65%That's more than half. | 2,550 |
| Depression screeningPatients screened for depression, with a follow-up plan if needed | 21%That's few of the people this applied to. | 3,990 |
| Diabetes eye examPeople with diabetes who got a retinal eye exam | 48%That's less than half. | 221 |
| Diabetes poorly controlledPeople with diabetes whose blood sugar stayed very high | 28%That's less than half. Better on this measure. | 221 |
| HIV screeningEligible patients who were screened for HIV | 12%That's few of the people this applied to. | 4,421 |
| Medications listed in the chartVisits where the current medication list was documented | 78%That's most of the people this applied to. | 10,680 |
| Patients can see their records onlinePatients who were given electronic access to their health information | 100%That's most of the people this applied to. | 533 |
| Prescriptions sent electronicallyPrescriptions sent to the pharmacy by computer instead of paper | 100%That's most of the people this applied to. | 1,494 |
| Statin prescribed when it protects the heartPeople at cardiovascular risk who were prescribed a statin | 50%That's more than half. | 1,100 |
| Weight checked, with a follow-up planPatients whose BMI was recorded and followed up if needed | 38%That's less than half. | 4,591 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Agreed to federal review of their records system
- Checks the state prescription-drug database before prescribing
- Did a security review of patient data
- Exchanges records both ways with other health systems
- High Priority Practices Guide of the Safety Assurance Factors for EHR Resilience (SAFER) Guides
- Improved the patient portal
- Lets patients read their visit notes
- Reports cases to public health electronically
- Reports immunizations to the state registry
- Shows lab and imaging costs when ordering tests
- Uses standard treatment protocols
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$117,512
Medicare paid this office $117,512 for 414 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 267 | $49,798 | $95 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 201 | $30,731 | $153 |
| Short return visit (20+ min) | 187 | $19,853 | $66 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 27 | $5,217 | $193 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 20 | $3,847 | $192 |
See all 9 services
| Return visit (30+ min) | 267 | $49,798 | $95 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 201 | $30,731 | $153 |
| Short return visit (20+ min) | 187 | $19,853 | $66 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 27 | $5,217 | $193 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 20 | $3,847 | $192 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 12 | $1,595 | $100 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 77 | $1,462 | $14 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 15 | $178 | $12 |
| Urinalysis, manual test | 33 | $143 | $3 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 1-10 | None |
Who their Medicare patients are
414 Original Medicare patients in 2024. Average age 72 · Under 65 3% · 85 and older 5% · Women 65% · Health risk score 0.76. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 62% · Coronary heart disease 15% · Diabetes 14% · Cancer 13% · Atrial fibrillation 12% · Depression 12% · Heart failure 7% · Chronic kidney disease 5% · COPD 5% · Stroke 4%.
The office billed $514,429, Medicare allowed $155,681 and paid $117,512; for 1,426 services of 37 kinds; $712 of it was for drugs given in the office and $116,800 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 414 | 1,426 | 72 | 0.76 | $514,429 | $117,512 |
| 2023 | 379 | 1,274 | 72 | 0.73 | $478,392 | $117,990 |
| 2022 | 400 | 1,976 | 72 | 0.72 | $615,836 | $149,616 |
| 2021 | 373 | 1,747 | 72 | 0.68 | $555,091 | $141,095 |
| 2020 | 350 | 1,646 | 72 | 0.70 | $447,091 | $115,905 |
| 2019 | 309 | 1,142 | 72 | 0.69 | $209,031 | $76,565 |
| 2018 | 237 | 847 | 72 | 0.68 | $90,255 | $52,627 |
| 2017 | 231 | 713 | 72 | 0.67 | $76,925 | $44,184 |
| 2016 | 223 | 685 | 72 | 0.70 | $73,184 | $43,788 |
| 2015 | 188 | 485 | 71 | 0.68 | $55,122 | $33,220 |
| 2014 | 191 | 617 | 71 | 0.62 | $67,365 | $39,461 |
| 2013 | 170 | 498 | 71 | 0.59 | $55,646 | $32,218 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 248 | $48,907 | $107 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 210 | $33,104 | $158 |
| Short return visit (20+ min) | 193 | $21,476 | $68 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 27 | $5,391 | $200 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 27 | $5,378 | $199 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 26 | $373 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $11 | None |
2022: 16 services
| Return visit (30+ min) | 257 | $50,508 | $106 |
| Short return visit (20+ min) | 268 | $39,694 | $75 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 212 | $33,587 | $158 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 32 | $6,410 | $200 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 22 | $4,415 | $201 |
| Long return visit (40+ min) | 14 | $2,084 | $149 |
| Aspiration and/or injection of fluid from large joint | 17 | $1,659 | $59 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 23 | $1,162 | $35 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 35 | $986 | $20 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 15 | $809 | $51 |
| New patient visit (45+ min) | 14 | $743 | $53 |
| Administration of influenza virus vaccine | 18 | $670 | $37 |
| Injection of drug or substance under skin or into muscle | 15 | $583 | $14 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 18 | $380 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 28 | $370 | $12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 28 | $23 | None |
2021: 14 services
| Return visit (30+ min) | 279 | $64,487 | $108 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 171 | $27,565 | $161 |
| Short return visit (20+ min) | 190 | $24,288 | $77 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 20 | $4,059 | $203 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 18 | $3,662 | $203 |
| Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | 46 | $2,155 | $35 |
| Aspiration and/or injection of fluid from large joint | 16 | $1,408 | $56 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 56 | $1,391 | $20 |
| Destruction of precancer skin growth, 1 growth | 12 | $1,263 | $66 |
| Administration of influenza virus vaccine | 27 | $583 | $22 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 11 | $564 | $51 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 27 | $554 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 24 | $368 | $14 |
| Injection, dexamethasone sodium phosphate, 1 mg | 22 | $23 | None |
2020: 14 services
| Return visit (30+ min) | 221 | $42,940 | $99 |
| Short return visit (20+ min) | 231 | $26,919 | $58 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 154 | $22,051 | $143 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 22 | $4,469 | $203 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 21 | $4,395 | $209 |
| New patient visit (30+ min) | 19 | $1,719 | $90 |
| Administration of influenza virus vaccine | 68 | $1,566 | $21 |
| Aspiration and/or injection of fluid from large joint | 11 | $1,182 | $59 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 40 | $807 | $19 |
| Influenza vaccine, quadrivalent derived from cell cultures | 21 | $582 | $28 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 29 | $470 | $16 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 12 | $256 | $21 |
| Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | 12 | $215 | $18 |
| Injection, dexamethasone sodium phosphate, 1 mg | 19 | $13 | None |
2019: 9 services
| Short return visit (20+ min) | 212 | $20,493 | $57 |
| Return visit (30+ min) | 141 | $19,804 | $90 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 134 | $18,158 | $136 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 25 | $4,825 | $193 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 24 | $4,739 | $197 |
| Administration of influenza virus vaccine | 58 | $1,189 | $20 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 58 | $1,014 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 22 | $369 | $15 |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $7 | None |
2018: 11 services
| Short return visit (20+ min) | 171 | $16,135 | $54 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 96 | $12,802 | $133 |
| Return visit (30+ min) | 76 | $8,048 | $82 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 16 | $2,996 | $187 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 13 | $2,519 | $194 |
| Aspiration and/or injection of fluid from large joint | 14 | $1,373 | $49 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 19 | $1,154 | $55 |
| Administration of influenza virus vaccine | 30 | $588 | $20 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 30 | $524 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 11 | $172 | $16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 18 | $6 | None |
2017: 6 services
| Short return visit (20+ min) | 190 | $17,907 | $49 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 88 | $11,581 | $132 |
| Return visit (30+ min) | 46 | $3,990 | $78 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 13 | $2,499 | $192 |
| Administration of influenza virus vaccine | 43 | $862 | $20 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 45 | $804 | $17 |
2016: 7 services
| Short return visit (20+ min) | 193 | $20,264 | $52 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 80 | $10,462 | $131 |
| Return visit (30+ min) | 33 | $3,411 | $90 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 15 | $2,862 | $191 |
| Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | 13 | $2,398 | $184 |
| Administration of influenza virus vaccine | 29 | $568 | $20 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 29 | $512 | $18 |
2015: 6 services
| Short return visit (20+ min) | 137 | $11,388 | $49 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 66 | $8,680 | $132 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 21 | $4,038 | $192 |
| Return visit (30+ min) | 31 | $3,062 | $87 |
| Administration of influenza virus vaccine | 21 | $412 | $20 |
| Influenza vaccine, quadrivalent, 0.5 ml dosage | 21 | $376 | $18 |
2014: 4 services
| Short return visit (20+ min) | 148 | $16,251 | $51 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 52 | $6,659 | $128 |
| Return visit (30+ min) | 50 | $4,760 | $79 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 23 | $4,333 | $188 |
2013: 4 services
| Short return visit (20+ min) | 137 | $14,702 | $52 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 25 | $4,729 | $189 |
| Return visit (30+ min) | 46 | $4,386 | $77 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 29 | $3,667 | $126 |
Drugs they prescribed that Part D paid
$155,882
Pharmacies billed $155,882 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (31 of 2,324) in 2024. At or below the middle of the specialty; the typical family practice clinician is at 2%.
2,069 generic and fewer than 11 brand-name prescriptions · $155,882 in drug cost · 44 antibiotic prescriptions to 31 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mounjaro | 23 | $23,356 | $1,015 |
| Eliquis | 17 | $17,575 | $1,034 |
| Estradiol | 35 | $3,472 | $99 |
| Atorvastatin | 245 | $2,359 | $10 |
| Liothyronine | 31 | $2,212 | $71 |
See all 54 drugs
| Mounjaro | 23 | $23,356 | $1,015 |
| Eliquis | 17 | $17,575 | $1,034 |
| Estradiol | 35 | $3,472 | $99 |
| Atorvastatin | 245 | $2,359 | $10 |
| Liothyronine | 31 | $2,212 | $71 |
| Yuvafem | 13 | $2,079 | $160 |
| Synthroid | 28 | $1,986 | $71 |
| Rosuvastatin | 77 | $1,849 | $24 |
| Levothyroxine | 166 | $1,816 | $11 |
| Wixela Inhub | 13 | $1,773 | $136 |
| Valsartan-Hydrochlorothiazide | 20 | $1,374 | $69 |
| Valacyclovir | 17 | $1,144 | $67 |
| Estradiol (Twice Weekly) | 11 | $1,097 | $100 |
| Metoprolol | 61 | $930 | $15 |
| Albuterol Sulfate Hfa | 26 | $900 | $35 |
| Bupropion Xl | 16 | $747 | $47 |
| Trazodone | 36 | $719 | $20 |
| Tamsulosin | 34 | $701 | $21 |
| Losartan | 95 | $647 | $7 |
| Oxybutynin Chloride Er | 16 | $643 | $40 |
| Lisinopril | 86 | $591 | $7 |
| Hydrocodone-Acetaminophen | 29 | $584 | $20 |
| Omeprazole | 51 | $570 | $11 |
| Valsartan | 12 | $528 | $44 |
| Escitalopram | 29 | $517 | $18 |
| Zolpidem | 55 | $507 | $9 |
| Montelukast | 26 | $459 | $18 |
| Simvastatin | 38 | $428 | $11 |
| Venlafaxine Hcl Er | 15 | $424 | $28 |
| Celecoxib | 23 | $392 | $17 |
| Lisinopril-Hydrochlorothiazide | 27 | $378 | $14 |
| Amlodipine Besylate | 55 | $354 | $6 |
| Olmesartan Medoxomil | 12 | $341 | $28 |
| Allopurinol | 28 | $338 | $12 |
| Losartan-Hydrochlorothiazide | 38 | $323 | $8 |
| Progesterone | 11 | $312 | $28 |
| Triamterene-Hydrochlorothiazid | 17 | $291 | $17 |
| Lorazepam | 42 | $267 | $6 |
| Hydrochlorothiazide | 38 | $256 | $7 |
| Metformin Hcl Er | 43 | $227 | $5 |
| Lovastatin | 15 | $198 | $13 |
| Pravastatin | 26 | $182 | $7 |
| Paroxetine | 11 | $180 | $16 |
| Clotrimazole-Betamethasone | 13 | $180 | $14 |
| Diphenoxylate-Atropine | 12 | $156 | $13 |
| Glipizide Er | 13 | $143 | $11 |
| Acyclovir | 13 | $135 | $10 |
| Alendronate | 12 | $107 | $9 |
| Metformin | 15 | $89 | $6 |
| Azithromycin | 14 | $72 | $5 |
| Alprazolam | 20 | $55 | $3 |
| Citalopram Hbr | 17 | $54 | $3 |
| Clonazepam | 17 | $48 | $3 |
| Meloxicam | 16 | $14 | $1 |
Year by year
| 2024 | 2,324 | 270 | 1% (31) | None | $155,882 |
| 2023 | 2,558 | 303 | 1% (28) | 11% | $161,468 |
| 2022 | 2,074 | 283 | 2% (40) | 10% | $117,333 |
| 2021 | 1,710 | 227 | 3% (49) | 9% | $95,621 |
| 2020 | 1,554 | 207 | 3% (44) | None | $95,745 |
| 2019 | 1,694 | 210 | 2% (37) | 16% | $113,904 |
| 2018 | 1,685 | 178 | 1% (23) | 15% | $101,597 |
| 2017 | 1,724 | 162 | 2% (31) | 16% | $86,525 |
| 2016 | 1,753 | 143 | 2% (40) | 15% | $95,064 |
| 2015 | 1,692 | 138 | 2% (32) | 16% | $82,190 |
| 2014 | 1,659 | 131 | 3% (44) | 18% | $76,601 |
| 2013 | 1,563 | 116 | 2% (25) | 23% | $70,611 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 62 drugs
| Eliquis | 18 | $18,816 | $1,045 |
| Spiriva Handihaler | 15 | $8,259 | $551 |
| Estradiol | 45 | $4,661 | $104 |
| Synthroid | 25 | $3,100 | $124 |
| Levothyroxine | 198 | $2,874 | $15 |
| Liothyronine | 42 | $2,786 | $66 |
| Atorvastatin | 253 | $2,446 | $10 |
| Yuvafem | 11 | $2,388 | $217 |
| Valacyclovir | 25 | $2,317 | $93 |
| Estradiol (Twice Weekly) | 16 | $1,817 | $114 |
| Rosuvastatin | 76 | $1,491 | $20 |
| Metoprolol | 71 | $1,364 | $19 |
| Trazodone | 37 | $1,262 | $34 |
| Valsartan-Hydrochlorothiazide | 18 | $1,104 | $61 |
| Losartan | 100 | $1,033 | $10 |
| Celecoxib | 21 | $1,030 | $49 |
| Venlafaxine Hcl Er | 33 | $920 | $28 |
| Lisinopril | 95 | $758 | $8 |
| Progesterone | 18 | $670 | $37 |
| Amlodipine Besylate | 72 | $650 | $9 |
| Tamsulosin | 18 | $612 | $34 |
| Allopurinol | 29 | $609 | $21 |
| Bupropion Xl | 19 | $608 | $32 |
| Ezetimibe | 13 | $576 | $44 |
| Escitalopram | 35 | $573 | $16 |
| Albuterol Sulfate Hfa | 16 | $571 | $36 |
| Propranolol | 12 | $536 | $45 |
| Valsartan | 13 | $533 | $41 |
| Hydrocodone-Acetaminophen | 27 | $529 | $20 |
| Montelukast | 21 | $466 | $22 |
| Losartan-Hydrochlorothiazide | 41 | $445 | $11 |
| Fluoxetine | 11 | $445 | $40 |
| Zolpidem | 49 | $428 | $9 |
| Lorazepam | 48 | $424 | $9 |
| Simvastatin | 45 | $418 | $9 |
| Lisinopril-Hydrochlorothiazide | 22 | $393 | $18 |
| Omeprazole | 50 | $381 | $8 |
| Potassium Chloride | 14 | $372 | $27 |
| Triamterene-Hydrochlorothiazid | 19 | $341 | $18 |
| Glipizide Er | 15 | $304 | $20 |
| Hydrochlorothiazide | 51 | $300 | $6 |
| Fluticasone Propionate | 13 | $297 | $23 |
| Metformin Hcl Er | 31 | $287 | $9 |
| Alendronate | 19 | $276 | $15 |
| Sertraline | 12 | $268 | $22 |
| Lovastatin | 21 | $226 | $11 |
| Ramipril | 11 | $213 | $19 |
| Meloxicam | 42 | $209 | $5 |
| Pravastatin | 21 | $206 | $10 |
| Acyclovir | 18 | $192 | $11 |
| Gabapentin | 12 | $141 | $12 |
| Nitrofurantoin Mono-Macro | 13 | $133 | $10 |
| Clonazepam | 29 | $89 | $3 |
| Cyclobenzaprine | 11 | $89 | $8 |
| Citalopram Hbr | 16 | $89 | $6 |
| Chlorthalidone | 13 | $78 | $6 |
| Azithromycin | 12 | $72 | $6 |
| Furosemide | 11 | $70 | $6 |
| Metformin | 16 | $42 | $3 |
| Alprazolam | 13 | $35 | $3 |
| Diazepam | 12 | $19 | $2 |
| Olmesartan Medoxomil | 13 | $4 | $0 |
2022: 47 drugs
| Fluticasone-Salmeterol | 15 | $6,313 | $421 |
| Estradiol | 40 | $3,813 | $95 |
| Synthroid | 35 | $3,516 | $100 |
| Rosuvastatin | 61 | $3,073 | $50 |
| Liothyronine | 34 | $2,781 | $82 |
| Valacyclovir | 25 | $2,659 | $106 |
| Atorvastatin | 197 | $2,555 | $13 |
| Levothyroxine | 133 | $2,251 | $17 |
| Celecoxib | 13 | $1,697 | $131 |
| Valsartan-Hydrochlorothiazide | 21 | $1,654 | $79 |
| Hydrocodone-Acetaminophen | 37 | $1,278 | $35 |
| Bupropion Xl | 23 | $1,129 | $49 |
| Metoprolol | 48 | $1,023 | $21 |
| Trazodone | 23 | $883 | $38 |
| Allopurinol | 31 | $755 | $24 |
| Albuterol Sulfate Hfa | 14 | $679 | $48 |
| Lisinopril | 63 | $581 | $9 |
| Venlafaxine Hcl Er | 33 | $578 | $18 |
| Montelukast | 18 | $561 | $31 |
| Escitalopram | 33 | $558 | $17 |
| Losartan-Hydrochlorothiazide | 25 | $465 | $19 |
| Losartan | 72 | $453 | $6 |
| Lorazepam | 43 | $413 | $10 |
| Omeprazole | 25 | $405 | $16 |
| Glipizide Er | 14 | $400 | $29 |
| Metformin Hcl Er | 38 | $383 | $10 |
| Lovastatin | 24 | $378 | $16 |
| Amlodipine Besylate | 60 | $329 | $5 |
| Simvastatin | 38 | $282 | $7 |
| Pravastatin | 27 | $255 | $9 |
| Zolpidem | 52 | $250 | $5 |
| Hydrochlorothiazide | 39 | $242 | $6 |
| Lisinopril-Hydrochlorothiazide | 19 | $239 | $13 |
| Citalopram Hbr | 22 | $225 | $10 |
| Sertraline | 14 | $159 | $11 |
| Atenolol | 11 | $157 | $14 |
| Alendronate | 15 | $143 | $10 |
| Paroxetine | 12 | $126 | $11 |
| Meloxicam | 19 | $116 | $6 |
| Gabapentin | 25 | $112 | $4 |
| Acyclovir | 14 | $99 | $7 |
| Triamterene-Hydrochlorothiazid | 13 | $89 | $7 |
| Alprazolam | 14 | $82 | $6 |
| Azithromycin | 12 | $77 | $6 |
| Clonazepam | 18 | $76 | $4 |
| Sulfamethoxazole-Trimethoprim | 12 | $75 | $6 |
| Metformin | 15 | $49 | $3 |
2021: 43 drugs
| Estradiol | 36 | $3,643 | $101 |
| Synthroid | 26 | $2,319 | $89 |
| Levothyroxine | 96 | $2,113 | $22 |
| Rosuvastatin | 42 | $2,097 | $50 |
| Atorvastatin | 144 | $2,020 | $14 |
| Liothyronine | 30 | $1,996 | $67 |
| Dotti | 14 | $1,937 | $138 |
| Metoprolol | 50 | $1,607 | $32 |
| Valacyclovir | 24 | $1,381 | $58 |
| Progesterone | 20 | $1,339 | $67 |
| Hydrocodone-Acetaminophen | 45 | $1,106 | $25 |
| Valsartan-Hydrochlorothiazide | 16 | $760 | $48 |
| Albuterol Sulfate Hfa | 13 | $653 | $50 |
| Pravastatin | 29 | $648 | $22 |
| Valsartan | 17 | $630 | $37 |
| Omeprazole | 33 | $608 | $18 |
| Losartan | 45 | $605 | $13 |
| Trazodone | 19 | $598 | $31 |
| Bupropion Xl | 11 | $571 | $52 |
| Losartan-Hydrochlorothiazide | 19 | $566 | $30 |
| Allopurinol | 24 | $549 | $23 |
| Lisinopril | 65 | $537 | $8 |
| Amlodipine Besylate | 46 | $509 | $11 |
| Glipizide Er | 12 | $458 | $38 |
| Lorazepam | 42 | $409 | $10 |
| Simvastatin | 28 | $362 | $13 |
| Lovastatin | 23 | $360 | $16 |
| Metformin Hcl Er | 23 | $353 | $15 |
| Hydrochlorothiazide | 26 | $342 | $13 |
| Potassium Chloride | 14 | $314 | $22 |
| Escitalopram | 23 | $274 | $12 |
| Venlafaxine Hcl Er | 22 | $269 | $12 |
| Lisinopril-Hydrochlorothiazide | 20 | $223 | $11 |
| Triamterene-Hydrochlorothiazid | 15 | $198 | $13 |
| Citalopram Hbr | 17 | $188 | $11 |
| Zolpidem | 20 | $184 | $9 |
| Alprazolam | 22 | $167 | $8 |
| Gabapentin | 20 | $159 | $8 |
| Sumatriptan | 13 | $149 | $11 |
| Clonazepam | 13 | $118 | $9 |
| Eszopiclone | 14 | $118 | $8 |
| Terbinafine | 15 | $108 | $7 |
| Meloxicam | 12 | $57 | $5 |
2020: 35 drugs
| Estradiol | 54 | $2,955 | $55 |
| Qvar Redihaler | 12 | $2,683 | $224 |
| Synthroid | 35 | $2,630 | $75 |
| Liothyronine | 40 | $2,571 | $64 |
| Levothyroxine | 89 | $2,230 | $25 |
| Rosuvastatin | 30 | $1,993 | $66 |
| Losartan-Hydrochlorothiazide | 24 | $1,915 | $80 |
| Atorvastatin | 116 | $1,886 | $16 |
| Metoprolol | 34 | $1,570 | $46 |
| Valacyclovir | 21 | $1,390 | $66 |
| Valsartan-Hydrochlorothiazide | 20 | $896 | $45 |
| Allopurinol | 30 | $718 | $24 |
| Hydrocodone-Acetaminophen | 42 | $712 | $17 |
| Valsartan | 11 | $622 | $57 |
| Losartan | 35 | $614 | $18 |
| Lisinopril | 48 | $551 | $11 |
| Fluticasone Propionate | 26 | $473 | $18 |
| Amlodipine Besylate | 39 | $426 | $11 |
| Simvastatin | 46 | $408 | $9 |
| Lovastatin | 16 | $389 | $24 |
| Tamsulosin | 13 | $379 | $29 |
| Diclofenac | 16 | $357 | $22 |
| Lorazepam | 45 | $329 | $7 |
| Pravastatin | 15 | $311 | $21 |
| Omeprazole | 16 | $303 | $19 |
| Triamterene-Hydrochlorothiazid | 19 | $232 | $12 |
| Alprazolam | 35 | $226 | $6 |
| Venlafaxine Hcl Er | 12 | $216 | $18 |
| Metformin Hcl Er | 15 | $205 | $14 |
| Atenolol | 11 | $181 | $16 |
| Hydrochlorothiazide | 19 | $167 | $9 |
| Zolpidem | 19 | $160 | $8 |
| Prednisone | 14 | $132 | $9 |
| Pantoprazole | 11 | $97 | $9 |
| Meloxicam | 14 | $39 | $3 |
2019: 39 drugs
| Janumet | 23 | $15,167 | $659 |
| Estradiol | 31 | $3,411 | $110 |
| Levothyroxine | 120 | $3,032 | $25 |
| Premarin | 12 | $2,624 | $219 |
| Liothyronine | 42 | $2,549 | $61 |
| Metoprolol | 44 | $2,456 | $56 |
| Atorvastatin | 122 | $2,130 | $17 |
| Synthroid | 31 | $2,030 | $65 |
| Rosuvastatin | 24 | $1,163 | $48 |
| Valsartan-Hydrochlorothiazide | 17 | $838 | $49 |
| Lisinopril | 59 | $774 | $13 |
| Hydrocodone-Acetaminophen | 37 | $726 | $20 |
| Allopurinol | 34 | $710 | $21 |
| Losartan | 34 | $647 | $19 |
| Simvastatin | 53 | $635 | $12 |
| Trazodone | 14 | $586 | $42 |
| Rabeprazole | 15 | $558 | $37 |
| Venlafaxine Hcl Er | 21 | $510 | $24 |
| Lorazepam | 61 | $476 | $8 |
| Amlodipine Besylate | 46 | $470 | $10 |
| Pravastatin | 17 | $375 | $22 |
| Lovastatin | 21 | $369 | $18 |
| Metformin Hcl Er | 23 | $366 | $16 |
| Diclofenac | 12 | $357 | $30 |
| Losartan-Hydrochlorothiazide | 25 | $347 | $14 |
| Omeprazole | 16 | $341 | $21 |
| Zolpidem | 37 | $328 | $9 |
| Triamterene-Hydrochlorothiazid | 18 | $266 | $15 |
| Potassium Chloride | 12 | $260 | $22 |
| Atenolol | 13 | $237 | $18 |
| Alprazolam | 25 | $234 | $9 |
| Fluticasone Propionate | 13 | $202 | $16 |
| Hydrochlorothiazide | 23 | $202 | $9 |
| Lisinopril-Hydrochlorothiazide | 15 | $195 | $13 |
| Escitalopram | 13 | $165 | $13 |
| Pantoprazole | 16 | $137 | $9 |
| Metformin | 14 | $105 | $7 |
| Sumatriptan | 11 | $100 | $9 |
| Alendronate | 13 | $69 | $5 |
2018: 40 drugs
| Janumet | 12 | $6,929 | $577 |
| Advair Diskus | 12 | $5,802 | $483 |
| Levothyroxine | 121 | $3,091 | $26 |
| Synthroid | 42 | $2,595 | $62 |
| Prempro | 13 | $2,324 | $179 |
| Estradiol | 33 | $2,309 | $70 |
| Liothyronine | 39 | $2,259 | $58 |
| Atorvastatin | 109 | $2,075 | $19 |
| Metoprolol | 46 | $2,020 | $44 |
| Proair Hfa | 15 | $1,434 | $96 |
| Tolterodine Tartrate Er | 12 | $1,074 | $90 |
| Lisinopril | 77 | $815 | $11 |
| Valsartan-Hydrochlorothiazide | 19 | $763 | $40 |
| Losartan | 51 | $755 | $15 |
| Gabapentin | 16 | $739 | $46 |
| Omeprazole | 32 | $709 | $22 |
| Allopurinol | 24 | $660 | $27 |
| Lovastatin | 25 | $642 | $26 |
| Hydrocodone-Acetaminophen | 21 | $577 | $27 |
| Simvastatin | 42 | $479 | $11 |
| Venlafaxine Hcl Er | 14 | $394 | $28 |
| Triamterene-Hydrochlorothiazid | 20 | $390 | $20 |
| Zolpidem | 38 | $368 | $10 |
| Losartan-Hydrochlorothiazide | 31 | $358 | $12 |
| Glipizide Er | 15 | $352 | $23 |
| Metformin Hcl Er | 31 | $345 | $11 |
| Ranitidine | 16 | $342 | $21 |
| Sertraline | 18 | $342 | $19 |
| Pravastatin | 18 | $312 | $17 |
| Lorazepam | 47 | $309 | $7 |
| Amlodipine Besylate | 36 | $250 | $7 |
| Hydrochlorothiazide | 38 | $224 | $6 |
| Irbesartan-Hydrochlorothiazide | 11 | $212 | $19 |
| Metoprolol | 17 | $183 | $11 |
| Escitalopram | 16 | $176 | $11 |
| Metformin | 14 | $171 | $12 |
| Alprazolam | 16 | $139 | $9 |
| Paroxetine | 15 | $122 | $8 |
| Alendronate | 22 | $108 | $5 |
| Lisinopril-Hydrochlorothiazide | 18 | $95 | $5 |
2017: 46 drugs
| Janumet | 17 | $6,591 | $388 |
| Spiriva | 11 | $4,039 | $367 |
| Levothyroxine | 118 | $3,130 | $27 |
| Prempro | 13 | $2,277 | $175 |
| Synthroid | 45 | $2,181 | $48 |
| Verapamil Er Pm | 12 | $2,047 | $171 |
| Tolterodine Tartrate Er | 12 | $2,037 | $170 |
| Atorvastatin | 110 | $1,969 | $18 |
| Fluoxetine | 12 | $1,618 | $135 |
| Liothyronine | 30 | $1,584 | $53 |
| Metoprolol | 32 | $1,204 | $38 |
| Lisinopril | 95 | $749 | $8 |
| Simvastatin | 73 | $666 | $9 |
| Zolpidem | 27 | $661 | $24 |
| Quinapril | 22 | $653 | $30 |
| Omeprazole | 33 | $635 | $19 |
| Losartan | 51 | $623 | $12 |
| Gabapentin | 18 | $595 | $33 |
| Lovastatin | 28 | $544 | $19 |
| Lorazepam | 50 | $501 | $10 |
| Hydrocodone-Acetaminophen | 31 | $489 | $16 |
| Triamterene-Hydrochlorothiazid | 29 | $487 | $17 |
| Losartan-Hydrochlorothiazide | 30 | $471 | $16 |
| Bupropion Xl | 14 | $439 | $31 |
| Glipizide Er | 22 | $396 | $18 |
| Pravastatin | 18 | $359 | $20 |
| Metformin Hcl Er | 37 | $338 | $9 |
| Allopurinol | 13 | $322 | $25 |
| Ranitidine | 16 | $306 | $19 |
| Amlodipine Besylate | 45 | $293 | $7 |
| Valsartan-Hydrochlorothiazide | 16 | $291 | $18 |
| Metformin | 17 | $287 | $17 |
| Potassium Chloride | 12 | $264 | $22 |
| Estradiol | 17 | $222 | $13 |
| Alprazolam | 20 | $218 | $11 |
| Amlodipine Besylate-Benazepril | 11 | $207 | $19 |
| Hydrochlorothiazide | 43 | $178 | $4 |
| Atenolol | 12 | $162 | $14 |
| Estarylla | 13 | $147 | $11 |
| Venlafaxine Hcl Er | 13 | $145 | $11 |
| Alendronate | 24 | $127 | $5 |
| Azithromycin | 17 | $122 | $7 |
| Lisinopril-Hydrochlorothiazide | 21 | $116 | $6 |
| Ramipril | 13 | $97 | $7 |
| Escitalopram | 14 | $90 | $6 |
| Ciprofloxacin | 11 | $69 | $6 |
2016: 45 drugs
| Spiriva | 11 | $3,672 | $334 |
| Levothyroxine | 153 | $3,567 | $23 |
| Tolterodine Tartrate Er | 17 | $3,547 | $209 |
| Diltiazem 24hr Er | 12 | $2,399 | $200 |
| Atorvastatin | 100 | $2,269 | $23 |
| Synthroid | 38 | $1,674 | $44 |
| Verapamil Er Pm | 14 | $1,425 | $102 |
| Metformin Hcl Er | 37 | $1,312 | $35 |
| Hydrocodone-Acetaminophen | 40 | $1,282 | $32 |
| Metoprolol | 35 | $1,244 | $36 |
| Liothyronine | 23 | $963 | $42 |
| Cytomel | 11 | $947 | $86 |
| Lisinopril | 107 | $929 | $9 |
| Gabapentin | 21 | $866 | $41 |
| Simvastatin | 66 | $755 | $11 |
| Diphenoxylate-Atropine | 13 | $583 | $45 |
| Venlafaxine Hcl Er | 24 | $573 | $24 |
| Zolpidem | 30 | $568 | $19 |
| Valsartan-Hydrochlorothiazide | 20 | $549 | $27 |
| Losartan-Hydrochlorothiazide | 40 | $544 | $14 |
| Omeprazole | 30 | $537 | $18 |
| Lovastatin | 33 | $499 | $15 |
| Losartan | 34 | $484 | $14 |
| Quinapril | 17 | $467 | $27 |
| Triamterene-Hydrochlorothiazid | 36 | $460 | $13 |
| Lorazepam | 45 | $442 | $10 |
| Potassium Chloride | 16 | $377 | $24 |
| Ranitidine | 19 | $370 | $19 |
| Alprazolam | 29 | $349 | $12 |
| Metformin | 23 | $305 | $13 |
| Hydrochlorothiazide | 49 | $298 | $6 |
| Amlodipine Besylate | 32 | $291 | $9 |
| Pravastatin | 14 | $285 | $20 |
| Escitalopram | 38 | $251 | $7 |
| Metoprolol | 13 | $245 | $19 |
| Allopurinol | 18 | $232 | $13 |
| Acyclovir | 12 | $229 | $19 |
| Glipizide Er | 22 | $206 | $9 |
| Pantoprazole | 15 | $198 | $13 |
| Atenolol | 13 | $183 | $14 |
| Sertraline | 12 | $174 | $14 |
| Alendronate | 23 | $152 | $7 |
| Estradiol | 12 | $145 | $12 |
| Lisinopril-Hydrochlorothiazide | 20 | $123 | $6 |
| Prednisone | 12 | $80 | $7 |
2015: 43 drugs
| Levothyroxine | 131 | $2,943 | $22 |
| Atorvastatin | 65 | $1,637 | $25 |
| Metoprolol | 40 | $1,575 | $39 |
| Liothyronine | 17 | $1,552 | $91 |
| Synthroid | 41 | $1,539 | $38 |
| Metformin Hcl Er | 44 | $1,329 | $30 |
| Verapamil Er Pm | 15 | $1,318 | $88 |
| Bupropion Xl | 31 | $1,188 | $38 |
| Zolpidem | 41 | $936 | $23 |
| Valsartan-Hydrochlorothiazide | 16 | $910 | $57 |
| Cytomel | 11 | $797 | $72 |
| Proair Hfa | 11 | $726 | $66 |
| Eszopiclone | 14 | $669 | $48 |
| Omeprazole | 51 | $629 | $12 |
| Simvastatin | 69 | $624 | $9 |
| Hydrocodone-Acetaminophen | 27 | $610 | $23 |
| Lisinopril | 84 | $579 | $7 |
| Triamterene-Hydrochlorothiazid | 31 | $450 | $15 |
| Potassium Chloride | 15 | $447 | $30 |
| Lorazepam | 29 | $444 | $15 |
| Venlafaxine Hcl Er | 13 | $438 | $34 |
| Diphenoxylate-Atropine | 20 | $424 | $21 |
| Losartan-Hydrochlorothiazide | 34 | $411 | $12 |
| Pravastatin | 16 | $379 | $24 |
| Allopurinol | 15 | $360 | $24 |
| Estradiol | 19 | $360 | $19 |
| Hydrochlorothiazide | 50 | $309 | $6 |
| Lovastatin | 34 | $302 | $9 |
| Ranitidine | 31 | $273 | $9 |
| Acyclovir | 19 | $262 | $14 |
| Losartan | 18 | $234 | $13 |
| Metoprolol | 21 | $232 | $11 |
| Pantoprazole | 19 | $218 | $11 |
| Escitalopram | 34 | $217 | $6 |
| Atenolol | 22 | $201 | $9 |
| Metformin | 19 | $184 | $10 |
| Amlodipine Besylate | 34 | $166 | $5 |
| Alendronate | 24 | $157 | $7 |
| Glipizide Er | 21 | $155 | $7 |
| Alprazolam | 25 | $152 | $6 |
| Sertraline | 13 | $123 | $9 |
| Ciprofloxacin | 13 | $84 | $6 |
| Paroxetine | 19 | $73 | $4 |
2014: 40 drugs
| Lunesta | 12 | $4,002 | $334 |
| Levothyroxine | 119 | $2,247 | $19 |
| Metformin Hcl Er | 41 | $1,912 | $47 |
| Liothyronine | 16 | $1,762 | $110 |
| Synthroid | 51 | $1,661 | $33 |
| Valsartan-Hydrochlorothiazide | 15 | $1,552 | $103 |
| Verapamil Er Pm | 15 | $1,322 | $88 |
| Atorvastatin | 59 | $1,162 | $20 |
| Metoprolol | 39 | $1,076 | $28 |
| Omeprazole | 61 | $965 | $16 |
| Bupropion Xl | 25 | $943 | $38 |
| Simvastatin | 63 | $806 | $13 |
| Hydrocodone-Acetaminophen | 38 | $718 | $19 |
| Acyclovir | 19 | $714 | $38 |
| Losartan-Hydrochlorothiazide | 44 | $655 | $15 |
| Venlafaxine Hcl Er | 20 | $481 | $24 |
| Potassium Chloride | 18 | $480 | $27 |
| Lisinopril | 55 | $427 | $8 |
| Zolpidem | 51 | $380 | $7 |
| Lovastatin | 29 | $373 | $13 |
| Losartan | 22 | $365 | $17 |
| Quinapril | 13 | $348 | $27 |
| Amlodipine Besylate | 47 | $310 | $7 |
| Allopurinol | 21 | $299 | $14 |
| Fluticasone Propionate | 14 | $275 | $20 |
| Triamterene-Hydrochlorothiazid | 21 | $272 | $13 |
| Hydrochlorothiazide | 40 | $260 | $6 |
| Metformin | 25 | $259 | $10 |
| Ranitidine | 28 | $233 | $8 |
| Atenolol | 29 | $222 | $8 |
| Estradiol | 28 | $217 | $8 |
| Pantoprazole | 17 | $214 | $13 |
| Lorazepam | 17 | $201 | $12 |
| Escitalopram | 21 | $197 | $9 |
| Pravastatin | 15 | $161 | $11 |
| Metoprolol | 17 | $135 | $8 |
| Fosinopril | 15 | $130 | $9 |
| Paroxetine | 16 | $119 | $7 |
| Azithromycin | 12 | $112 | $9 |
| Donepezil | 11 | $74 | $7 |
2013: 41 drugs
| Detrol La | 20 | $4,291 | $215 |
| Valsartan-Hydrochlorothiazide | 17 | $2,640 | $155 |
| Prempro | 22 | $2,155 | $98 |
| Atorvastatin | 38 | $1,335 | $35 |
| Levothyroxine | 97 | $1,331 | $14 |
| Simvastatin | 78 | $1,166 | $15 |
| Omeprazole | 56 | $1,091 | $19 |
| Verapamil Er Pm | 13 | $1,057 | $81 |
| Oxybutynin Chloride Er | 12 | $1,052 | $88 |
| Synthroid | 49 | $986 | $20 |
| Bupropion Xl | 22 | $835 | $38 |
| Metoprolol | 27 | $817 | $30 |
| Losartan-Hydrochlorothiazide | 39 | $770 | $20 |
| Metronidazole | 12 | $761 | $63 |
| Potassium Chloride | 18 | $648 | $36 |
| Amlodipine Besylate | 66 | $610 | $9 |
| Losartan | 35 | $609 | $17 |
| Zolpidem | 69 | $569 | $8 |
| Quinapril | 25 | $567 | $23 |
| Spironolactone | 11 | $514 | $47 |
| Lovastatin | 25 | $386 | $15 |
| Hydrochlorothiazide | 44 | $382 | $9 |
| Metformin | 36 | $351 | $10 |
| Glipizide Er | 12 | $315 | $26 |
| Acyclovir | 19 | $307 | $16 |
| Escitalopram | 14 | $301 | $21 |
| Atenolol | 37 | $295 | $8 |
| Venlafaxine Hcl Er | 12 | $292 | $24 |
| Hydrocodone-Acetaminophen | 24 | $284 | $12 |
| Triamterene-Hctz | 18 | $267 | $15 |
| Fosinopril | 15 | $248 | $17 |
| Ranitidine | 18 | $219 | $12 |
| Estradiol | 27 | $199 | $7 |
| Lisinopril | 27 | $177 | $7 |
| Metformin Hcl Er | 19 | $159 | $8 |
| Allopurinol | 11 | $148 | $13 |
| Donepezil | 12 | $134 | $11 |
| Paroxetine | 14 | $128 | $9 |
| Lorazepam | 12 | $105 | $9 |
| Citalopram Hbr | 13 | $71 | $5 |
| Furosemide | 13 | $50 | $4 |
Money from drug and device companies
$601 in 2025
| 2025 | 12 | 32 | None | $601 |
| 2024 | 9 | 53 | None | $893 |
| 2023 | 12 | 69 | None | $1,022 |
| 2022 | 6 | 44 | None | $478 |
| 2021 | 4 | 20 | None | $217 |
| 2020 | 11 | 23 | None | $576 |
| 2019 | 14 | 58 | None | $833 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| InSightec | Exablate | $143 | 1 payment
|
| Abbvie | Vraylar | $139 | 16 payments
|
| GlaxoSmithKline | Arexvy | $77 | 3 payments
|
| Lilly USA | Mounjaro | $50 | 3 payments
|
| Exact Sciences | Cologuard Collection Kit | $48 | 2 payments
|
| Novo Nordisk | Ozempic | $27 | 1 payment
|
See all 32 published payments
| Abbvie | Meals · 2025-12-03 | Qulipta | $6 |
| Abbvie | Meals · 2025-11-12 | Vraylar | $3 |
| Abbvie | Meals · 2025-11-05 | Vraylar | $5 |
| Abbvie | Meals · 2025-11-01 | Vraylar | $20 |
| Amgen | Meals · 2025-10-22 | Repatha | $17 |
| Abbvie | Meals · 2025-10-03 | Vraylar | $6 |
| Abbvie | Meals · 2025-09-18 | Vraylar | $6 |
| Exact Sciences | Meals · 2025-09-14 | Cologuard Collection Kit | $25 |
| GlaxoSmithKline | Meals · 2025-08-27 | Arexvy | $22 |
| InSightec | Meals · 2025-08-26 | Exablate | $143 |
| Abbvie | Meals · 2025-07-08 | Vraylar | $28 |
| Lilly USA | Meals · 2025-06-17 | Mounjaro | $20 |
| Abbvie | Meals · 2025-05-02 | Vraylar | $2 |
| GlaxoSmithKline | Meals · 2025-04-29 | Arexvy | $29 |
| Currax Pharmaceuticals | Meals · 2025-04-23 | Contrave | $16 |
| Abbvie | Meals · 2025-04-16 | Vraylar | $6 |
| Hologic Sales and Service | Meals · 2025-03-26 | Acessa Provu System | $22 |
| Abbvie | Meals · 2025-03-19 | Vraylar | $24 |
| Pfizer | Meals · 2025-03-11 | Nurtec Odt | $25 |
| Abbvie | Meals · 2025-03-06 | Qulipta | $5 |
| Abbvie | Meals · 2025-03-05 | Vraylar | $6 |
| CooperSurgical | Meals · 2025-03-04 | Paragard T 380a | $17 |
| Novo Nordisk | Meals · 2025-02-28 | Ozempic | $27 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-02-26 | Trintellix | $19 |
| Lilly USA | Meals · 2025-02-07 | Mounjaro | $15 |
| Abbvie | Meals · 2025-02-05 | Vraylar | $6 |
| GlaxoSmithKline | Meals · 2025-02-03 | Trelegy Ellipta | $26 |
| Abbvie | Meals · 2025-01-22 | Qulipta | $12 |
| Exact Sciences | Meals · 2025-01-17 | Cologuard Collection Kit | $23 |
| Abbvie | Meals · 2025-01-16 | Vraylar | $3 |
| Lilly USA | Meals · 2025-01-09 | Mounjaro | $15 |
| Abbvie | Meals · 2025-01-08 | Qulipta | $2 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $893
| Abbvie | Vraylar | $333 | 26 payments
|
| GlaxoSmithKline | Arexvy | $181 | 10 payments
|
| Novo Nordisk | Ozempic | $109 | 5 payments
|
| Pfizer | Nurtec Odt | $106 | 5 payments
|
| Exact Sciences | Cologuard Collection Kit | $46 | 2 payments
|
| Lilly USA | Mounjaro | $36 | 2 payments
|
| Astellas Pharma US | Veozah | $33 | 1 payment
|
| Amgen | Krystexxa | $32 | 1 payment
|
| Bioventus | Durolane | $16 | 1 payment
|
2023: $1,022
| Abbvie | Vraylar | $529 | 49 payments
|
| GlaxoSmithKline | Arexvy | $138 | 7 payments
|
| NuVasive | Xlif | $100 | 1 payment
|
| Pfizer | Nurtec Odt | $70 | 4 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $33 | 1 payment
|
| Fidia Pharma USA | Hymovis | $33 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $24 | 1 payment
|
| Myriad Women's Health | Myrisk | $23 | 1 payment
|
| CooperSurgical | Paragard T 380a | $20 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $18 | 1 payment
|
| Bioventus | Durolane | $18 | 1 payment
|
| Lilly USA | Mounjaro | $17 | 1 payment
|
2022: $478
| Abbvie | Ubrelvy | $388 | 37 payments
|
| VBI Vaccines (Delaware) | Prehevbrio | $24 | 1 payment
|
| Organon | Nexplanon | $22 | 3 payments
|
| Novo Nordisk | Rybelsus | $17 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $14 | 1 payment
|
| Bausch Health US | Aplenzin | $13 | 1 payment
|
2021: $217
| AbbVie | Ubrelvy | $140 | 16 payments
|
| Amarin Pharma | Vascepa | $34 | 2 payments
|
| Novo Nordisk | Ozempic | $22 | 1 payment
|
| Biohaven Pharmaceuticals | Nurtec Odt | $20 | 1 payment
|
2020: $576
| Teva Pharmaceuticals USA | Ajovy | $232 | 7 payments
|
| Amgen | Aimovig | $58 | 2 payments
|
| TherapeuticsMD | Annovera | $53 | 3 payments
|
| Allergan | Ubrelvy | $48 | 2 payments
|
| Lilly USA | Trulicity | $39 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $34 | 2 payments
|
| Eisai | Dayvigo | $24 | 1 payment
|
| AMAG Pharmaceuticals | Vyleesi | $23 | 1 payment
|
| Bausch Health US | Aplenzin | $23 | 1 payment
|
| Merck Sharp & Dohme | Nexplanon | $22 | 1 payment
|
| AbbVie | Synthroid | $21 | 1 payment
|
2019: $833
| Teva Pharmaceuticals USA | Ajovy | $312 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $119 | 28 payments
|
| TherapeuticsMD | Imvexxy | $113 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Bevespi Aerosphere | $52 | 3 payments
|
| Merck Sharp & Dohme | Nexplanon | $43 | 3 payments
|
| AMAG Pharmaceuticals | Vyleesi | $31 | 2 payments
|
| Amgen | Aimovig | $29 | 1 payment
|
| Medtronic Vascular | Endurant | $26 | 1 payment
|
| Fidia Pharma USA | Hymovis | $24 | 1 payment
|
| AbbVie | None | $20 | 1 payment
|
| DePuy Synthes Sales | Monovisc | $19 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $17 | 1 payment
|
| Lilly USA | Basaglar | $16 | 1 payment
|
| Allergan | Lo Loestrin Fe | $13 | 1 payment
|
Professional record
- NPI
- 1932123106
- Licence
- CA A061360
- Trained
- University of California, San Diego School of Medicine, 1995
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207QS0010X (207QS0010X)
- Mailing address
- 221 E Hacienda Ave, Ste B, Campbell, CA, 95008
- NPI first listed
- 2006-07-27
- NPI last updated
- 2018-08-21
This is when the NPI record was last certified, not a medical board exam.